Chao Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chao Gu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Xinhua Gu
2 shared publicationsYan Zhang
2 shared publicationsZheng Yuan
2 shared publications- Bin Li
State Key Laboratory of Natural Medicines and School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing China
1 shared publication - Bowen Li
Gastric Cancer Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China
1 shared publication Chenliang Cao
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by KEAI Publishing in Genes & Diseases
AMPKα1-mediated phosphorylation of ZDHHC17 promotes TROP2 palmitoylation and stabilization to drive gastric cancer progression
- 1 August 2026
- Published by KEAI Publishing in Genes & Diseases
Open AccessAMPKα1-mediated phosphorylation of ZDHHC17 promotes TROP2 palmitoylation and stabilization to drive gastric cancer progression
- Open Access
- 31 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e013763
Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in KRAS -mutant colorectal cancer
Background: KRAS is one of the most frequently mutated genes in colorectal cancer (CRC) and plays a crucial role in tumorigenesis, progression, immune evasion, and treatment resistance. The pronounced heterogeneity within KRAS -mutant CRC highlights the urgent need for more precise and personalized therapeutic approaches. Methods: To investigate this heterogeneity, we employed single-cell RNA sequencing and spatial transcriptomics to comprehensively characterize the tumor microenvironment of KRAS -mutant CRC. Data preprocessing and clustering were performed using Scanpy. Spatial cell-type deconvolution was conducted via Cell2location, whereas intercellular communication and spatial dependencies were analyzed using CellChat, MISTy, and stLearn. Results: Our analyses revealed that KRAS -mutant tumor epithelial cells recruit Mono_ S100A8 monocytes via the MDK_SDC4 signaling axis. Concurrently, surrounding Fib_ CTHRC1 fibroblasts secrete collagen, which interacts with integrin receptors on KRAS -mutant epithelial cells and contributes to the exclusion of lymphocyte infiltration. Conclusion: These cellular components collaboratively established an immunosuppressive spatial niche. These findings offer novel theoretical insights and potential targets for the development of immunoregulatory strategies tailored to KRAS -mutant CRC.
- 31 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e013763
Open AccessSingle-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in KRAS -mutant colorectal cancer
Background: KRAS is one of the most frequently mutated genes in colorectal cancer (CRC) and plays a crucial role in tumorigenesis, progression, immune evasion, and treatment resistance. The pronounced heterogeneity within KRAS -mutant CRC highlights the urgent need for more precise and personalized therapeutic approaches. Methods: To investigate this heterogeneity, we employed single-cell RNA sequencing and spatial transcriptomics to comprehensively characterize the tumor microenvironment of KRAS -mutant CRC. Data preprocessing and clustering were performed using Scanpy. Spatial cell-type deconvolution was conducted via Cell2location, whereas intercellular communication and spatial dependencies were analyzed using CellChat, MISTy, and stLearn. Results: Our analyses revealed that KRAS -mutant tumor epithelial cells recruit Mono_ S100A8 monocytes via the MDK_SDC4 signaling axis. Concurrently, surrounding Fib_ CTHRC1 fibroblasts secrete collagen, which interacts with integrin receptors on KRAS -mutant epithelial cells and contributes to the exclusion of lymphocyte infiltration. Conclusion: These cellular components collaboratively established an immunosuppressive spatial niche. These findings offer novel theoretical insights and potential targets for the development of immunoregulatory strategies tailored to KRAS -mutant CRC.
- Open Access
- 1 January 2022
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 16
Quantification of Tumor Abnormal Proteins in the Diagnosis and Postoperative Prognostic Evaluation of Gastric Cancer
Background: Abnormal glycosylation of proteins has been identified in almost all types of cancers and is closely related to the cancer progression, metastasis, and survival of cancer patients. This study was to explore the values of serum tumor abnormal protein (TAP), an abnormal glycochain protein, in the diagnosis and prognosis of gastric cancer (GC). Methods: A total of 335 GC patients were included as the study group, and another 335 subjects served as the control group. Tumor abnormal protein expression was compared between the 2 groups. Correlation analysis was used to assess the correlations of TAP with clinicopathological factors. Gastric cancer patients were divided into training set and test set at a ratio of 2:1. Univariate and multivariate Cox regression analyses in training set were used to evaluate the prognostic significance of TAP in GC patients and explore the independent risk factors for overall survival (OS) and disease-free survival (DFS) to establish a prognostic model, followed by testing of the model. According to the median of TAP, 335 GC patients were divided into 2 groups to plot the survival curves of OS and DFS. Results: Tumor abnormal protein expression in the study group was significantly higher than in the control group. Taking the best cut-off value of TAP (110.128 μm2) as the diagnostic criteria for GC, the sensitivity and specificity of TAP were 83.58% and 97.61%, respectively, and the area under the receiver operating characteristics (ROC) curve was 0.935, which was not inferior to computed tomography (CT). Tumor abnormal protein expression was an independent risk factor for OS and DFS. The prognostic predictive value of TAP was better than that of pathological stage in GC patients. The model with TAP was effective in predicting prognosis. Conclusion: Tumor abnormal protein is an effective indicator for early screening and prognostic evaluation of GC and can also assist the clinical diagnosis and treatment of GC.
- 1 January 2022
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 16
Open AccessQuantification of Tumor Abnormal Proteins in the Diagnosis and Postoperative Prognostic Evaluation of Gastric Cancer
Background: Abnormal glycosylation of proteins has been identified in almost all types of cancers and is closely related to the cancer progression, metastasis, and survival of cancer patients. This study was to explore the values of serum tumor abnormal protein (TAP), an abnormal glycochain protein, in the diagnosis and prognosis of gastric cancer (GC). Methods: A total of 335 GC patients were included as the study group, and another 335 subjects served as the control group. Tumor abnormal protein expression was compared between the 2 groups. Correlation analysis was used to assess the correlations of TAP with clinicopathological factors. Gastric cancer patients were divided into training set and test set at a ratio of 2:1. Univariate and multivariate Cox regression analyses in training set were used to evaluate the prognostic significance of TAP in GC patients and explore the independent risk factors for overall survival (OS) and disease-free survival (DFS) to establish a prognostic model, followed by testing of the model. According to the median of TAP, 335 GC patients were divided into 2 groups to plot the survival curves of OS and DFS. Results: Tumor abnormal protein expression in the study group was significantly higher than in the control group. Taking the best cut-off value of TAP (110.128 μm2) as the diagnostic criteria for GC, the sensitivity and specificity of TAP were 83.58% and 97.61%, respectively, and the area under the receiver operating characteristics (ROC) curve was 0.935, which was not inferior to computed tomography (CT). Tumor abnormal protein expression was an independent risk factor for OS and DFS. The prognostic predictive value of TAP was better than that of pathological stage in GC patients. The model with TAP was effective in predicting prognosis. Conclusion: Tumor abnormal protein is an effective indicator for early screening and prognostic evaluation of GC and can also assist the clinical diagnosis and treatment of GC.
- Open Access
- 21 July 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (3) , 1554-1560
Stevens–Johnson syndrome associated with TS‐1 in a patient with gastric cancer: A case report
- 21 July 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (3) , 1554-1560
Open AccessStevens–Johnson syndrome associated with TS‐1 in a patient with gastric cancer: A case report
- Open Access
- 1 April 2015
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10, 2765-74
The potential of follicle-stimulating hormone peptide-modified triptolide-loaded nanoparticles to induce a mouse model of premature ovarian insufficiency
The use of triptolide (TP) is limited by its poor water solubility and severe toxicity. In this study, we developed an active drug delivery system (TP-loaded nanoparticles) that could help improve the water solubility of TP and decrease its toxicity. Then, we investigated whether TP-loaded nanoparticles could be used to establish a novel premature ovarian insufficiency mouse model. The mice treated with TP-loaded nanoparticles for 35 days displayed normal growth, decreased serum antimullerian hormone, prominent ovarian fibrosis and vacuolar changes, fewer follicles and corpus lutea, increased collapsed oocytes and follicle apoptosis, and sterility. In conclusion, this model appears to show the reproductive characteristics associated with premature ovarian insufficiency in women and will allow us to study the mechanism of the effects of traditional Chinese medicine on gonadal toxicity.
- 1 April 2015
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10, 2765-74
Open AccessThe potential of follicle-stimulating hormone peptide-modified triptolide-loaded nanoparticles to induce a mouse model of premature ovarian insufficiency
The use of triptolide (TP) is limited by its poor water solubility and severe toxicity. In this study, we developed an active drug delivery system (TP-loaded nanoparticles) that could help improve the water solubility of TP and decrease its toxicity. Then, we investigated whether TP-loaded nanoparticles could be used to establish a novel premature ovarian insufficiency mouse model. The mice treated with TP-loaded nanoparticles for 35 days displayed normal growth, decreased serum antimullerian hormone, prominent ovarian fibrosis and vacuolar changes, fewer follicles and corpus lutea, increased collapsed oocytes and follicle apoptosis, and sterility. In conclusion, this model appears to show the reproductive characteristics associated with premature ovarian insufficiency in women and will allow us to study the mechanism of the effects of traditional Chinese medicine on gonadal toxicity.
- Open Access
- 5 September 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 6 (5) , 1050-1056
Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer
Ovarian cancer causes more deaths than any other type of female reproductive cancer. The development of new therapeutic approaches is required due to the low survival rate using routine methods. The goal of this study was to investigate the effect of the gene silencing of mediator complex subunit 19 (MED19) on cell viability and tumor growth in ovarian cancer. Immunohistochemistry was used to characterize the expression of MED19 in human ovarian cancer tissues. Lentivirus-mediated RNAi was employed to downregulate endogenous MED19 expression in SKOV-3 and HEY ovarian cancer cells. MTT assay, BrdU incorporation assay, colony formation assay, cell cycle analysis and tumor xenografts in nude mice were performed to determine the effects of MED19 silencing on cell viability and tumor growth in vitro and in vivo. The data showed that the expression of MED19 in human ovarian cancer tissues correlated with the level of tumor malignancy. The downregulation of MED19 in ovarian cancer cells significantly inhibited cell proliferation and colony formation in vitro and led to cell cycle arrest in the G0/G1 phase. MED19 RNAi significantly inhibited ovarian cancer tumor growth in engrafted nude mice. Our findings reveal that the knockdown of MED19 by lentivirus-mediated RNAi may be useful in the treatment of human ovarian cancer.
- 5 September 2012
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 6 (5) , 1050-1056
Open AccessKnockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer
Ovarian cancer causes more deaths than any other type of female reproductive cancer. The development of new therapeutic approaches is required due to the low survival rate using routine methods. The goal of this study was to investigate the effect of the gene silencing of mediator complex subunit 19 (MED19) on cell viability and tumor growth in ovarian cancer. Immunohistochemistry was used to characterize the expression of MED19 in human ovarian cancer tissues. Lentivirus-mediated RNAi was employed to downregulate endogenous MED19 expression in SKOV-3 and HEY ovarian cancer cells. MTT assay, BrdU incorporation assay, colony formation assay, cell cycle analysis and tumor xenografts in nude mice were performed to determine the effects of MED19 silencing on cell viability and tumor growth in vitro and in vivo. The data showed that the expression of MED19 in human ovarian cancer tissues correlated with the level of tumor malignancy. The downregulation of MED19 in ovarian cancer cells significantly inhibited cell proliferation and colony formation in vitro and led to cell cycle arrest in the G0/G1 phase. MED19 RNAi significantly inhibited ovarian cancer tumor growth in engrafted nude mice. Our findings reveal that the knockdown of MED19 by lentivirus-mediated RNAi may be useful in the treatment of human ovarian cancer.